Kent William Mouw MD
Radiation Oncologist, Brigham & Women's Hospital/Dana-Farber Cancer Institute
Join to View Full Profile
75 Francis StBoston, MA 02115
Phone+1 617-732-5500
Dr. Mouw is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2011 - 2015- Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2010 - 2011
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010
Certifications & Licensure
MA State Medical License 2012 - 2027
American Board of Radiology Radiation Oncology
Clinical Trials
- Avelumab and Radiation in Muscle-Invasive Bladder Cancer Start of enrollment: 2018 Dec 13
Publications & Presentations
PubMed
- Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.Judit Börcsök, Diyavarshini Gopaul, Daphne Devesa-Serrano, Clémence Mooser, Nicolas Jonsson
The Journal of Clinical Investigation. 2025-08-15 - 1 citationsRelationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.Gopa Iyer, Woonyoung Choi, Bin Luo, Filipe Carvalho, Timothy Hanlon
JCO Precision Oncology. 2025-07-01 - 3 citationsBladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.Shilpa Gupta, Patrick J Hensley, Roger Li, Ananya Choudhury, Siamak Daneshmand
European Urology. 2025-04-22
Journal Articles
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicKent W Mouw, Paul L Nguyen, JAMA Oncology
Authored Content
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020
Press Mentions
- Active Surveillance for Low-Risk Prostate Cancer in Black PatientsMay 22nd, 2019
ASTRO 2025: Discussant – Bladder and Post-Prostatectomy RadiationOctober 1st, 2025
Grant Support
- Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder CancerDANA-FARBER CANCER INST2024–2029
- Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder CancerDANA-FARBER CANCER INST2024–2029
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder CancerDANA-FARBER CANCER INST2024–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
